BioCryst Pharmaceuticals Inc. (BCRX)

2.68
0.09 3.50
NASDAQ : Health Technology
Prev Close 2.59
Open 2.60
Day Low/High 2.55 / 2.68
52 Wk Low/High 2.54 / 9.95
Volume 1.06M
Avg Volume 2.36M
Exchange NASDAQ
Shares Outstanding 110.44M
Market Cap 284.93M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
3 Pharma Stocks Leaping on Unusual Volume

3 Pharma Stocks Leaping on Unusual Volume

Stocks that are making large moves like these are favorites among short-term traders because they can jump into these names and try to capture some of that massive volatility.

BioCryst To Present At J.P. Morgan Healthcare Conference

BioCryst To Present At J.P. Morgan Healthcare Conference

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Jon Stonehouse, President and Chief Executive Officer of BioCryst is scheduled to present and provide a corporate summary and update regarding...

The Worst Biotech CEO of 2012 Is...

The Worst Biotech CEO of 2012 Is...

Cell Therapeutics' Jim Bianco Wins! Amarin CEO Joe Zakrzewski tries to steal election with last-minute plot.

BioCryst Pharmaceuticals Announces Focused Corporate Strategy And Restructuring

BioCryst Pharmaceuticals Announces Focused Corporate Strategy And Restructuring

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that in response to recent events and an assessment of its assets, the Company is restructuring and implementing a focused strategy to advance its ...

Your Vote Counts: Who Is the Worst Biotech CEO of 2012?

Your Vote Counts: Who Is the Worst Biotech CEO of 2012?

Readers get to decide which of the CEOs from BioSante, BioCryst, Peregrine or Cell Therapeutics deserve the dishonor.

BioCryst Pharmaceuticals And Presidio Pharmaceuticals Mutually Terminate Merger Transaction

BioCryst Pharmaceuticals And Presidio Pharmaceuticals Mutually Terminate Merger Transaction

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and privately held Presidio Pharmaceuticals, Inc.

5 Biotech Stocks Rising on Unusual Volume

5 Biotech Stocks Rising on Unusual Volume

Here are several biotech and pharma stocks under $10 that are making large moves to the upside today.

BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective Against Yellow Fever In A Preclinical Disease Model

BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective Against Yellow Fever In A Preclinical Disease Model

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced proof-of-principle data demonstrating that BCX4430 is efficacious and well tolerated in a preclinical disease model for evaluating efficacy against...

BioCryst Provides Corporate Update And Reports Third Quarter 2012 Financial Results

BioCryst Provides Corporate Update And Reports Third Quarter 2012 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the third quarter and nine months ended September 30, 2012.

BioCryst Announces Outcome From The Peramivir Phase 3 Interim Analysis

BioCryst Announces Outcome From The Peramivir Phase 3 Interim Analysis

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza.

BioCryst To Report Third Quarter 2012 Financial Results On November 8, 2012

BioCryst To Report Third Quarter 2012 Financial Results On November 8, 2012

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third quarter 2012 financial results will be released on Thursday, November 8, 2012.

BioCryst Provides Update Regarding BCX5191 Development Plan Following Discussion With FDA

BioCryst Provides Update Regarding BCX5191 Development Plan Following Discussion With FDA

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the withdrawal of its Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.

BioCryst Pharmaceuticals And Presidio Pharmaceuticals To Merge

BioCryst Pharmaceuticals And Presidio Pharmaceuticals To Merge

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and privately held Presidio Pharmaceuticals, Inc.

BioCryst Provides Corporate Update And Reports Second Quarter 2012 Financial Results

BioCryst Provides Corporate Update And Reports Second Quarter 2012 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter and six months ended June 30, 2012.

Buy or Get Out of the Way

Market players are adding long exposure as the market runs away from them.

Biotech Stock Mailbag: Amarin, Sarepta

Biotech Stock Mailbag: Amarin, Sarepta

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

BioCryst Announces Positive Results From Two Ulodesine Phase 2 Trials In Patients With Gout

BioCryst Announces Positive Results From Two Ulodesine Phase 2 Trials In Patients With Gout

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208)...

BioCryst To Report Second Quarter 2012 Financial Results On August 2, 2012

BioCryst To Report Second Quarter 2012 Financial Results On August 2, 2012

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its second quarter 2012 financial results will be released on Thursday, August 2, 2012.

BioCryst To Present At The 7th Annual JMP Securities Healthcare Conference

BioCryst To Present At The 7th Annual JMP Securities Healthcare Conference

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Dr.

4 Stocks Poised to Break Out

4 Stocks Poised to Break Out

The LiveDeal breakout we mentioned yesterday has happened today! Trading stocks that trigger major breakouts can lead to massive profits.

BioCryst Presents Results From Its BCX4208 Gout Program At The Annual European Congress Of Rheumatology

BioCryst Presents Results From Its BCX4208 Gout Program At The Annual European Congress Of Rheumatology

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that additional safety and efficacy results from its BCX4208 gout program will be presented at the Annual European Congress of Rheumatology hosted...

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the ...

Hot Biotech Stocks Traded by Hedge Funds in First Quarter

Hot Biotech Stocks Traded by Hedge Funds in First Quarter

A closer look at 13F regulatory filings in the biotech sector for the first quarter.

BioCryst Provides Corporate Update And Reports First Quarter 2012 Financial Results

BioCryst Provides Corporate Update And Reports First Quarter 2012 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2012.

BioCryst To Report First Quarter 2012 Financial Results On May 7, 2012

BioCryst To Report First Quarter 2012 Financial Results On May 7, 2012

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2012 financial results will be released on Monday, May 7, 2012.

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the...

Biotech Stock Mailbag: Vivus, Chelsea, BioCryst

Biotech Stock Mailbag: Vivus, Chelsea, BioCryst

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

BioCryst Reports Fourth Quarter And Full Year 2011 Financial Results

BioCryst Reports Fourth Quarter And Full Year 2011 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2011.

BioCryst Announces Promising Results From Preclinical Studies Of BCX5191 For Hepatitis C

BioCryst Announces Promising Results From Preclinical Studies Of BCX5191 For Hepatitis C

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced favorable preclinical results for BCX5191, a novel adenine nucleoside analog targeting viral RNA polymerase for the potential treatment of hepatitis ...

BioCryst To Announce Fourth Quarter And Full Year 2011 Financial Results On February 16, 2012

BioCryst To Announce Fourth Quarter And Full Year 2011 Financial Results On February 16, 2012

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that its fourth quarter and full year 2011 financial results will be released on Thursday, February 16, 2012.

TheStreet Quant Rating: D- (Sell)